JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
22/12/25 - 17:25
2026 Annual Corporate Events Calendar (117.34 KB)
22/12/25 - 14:36
The Board of Directors approved to submit to the Shareholders' Meeting the authorization for the purchase and cancellation of treasury shares for the purpose of shareholder remuneration. Ordinary and extraordinary shareholders' meeting convened. (125.84 KB)
24/11/25 - 11:10
Diasorin submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance (128.44 KB)
18/11/25 - 6:30
Diasorin, in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark (147.94 KB)
05/11/25 - 17:46
Diasorin’s Board of Directors approves results for the first 9 months of 2025. FY 2025 Guidance revised (255.77 KB)
31/10/25 - 10:12
Diasorin receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration (132.55 KB)
22/10/25 - 7:41
Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX (125.42 KB)
19/09/25 - 9:34
Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)
08/09/25 - 11:16
New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)
31/07/25 - 16:22
Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)
02/07/25 - 8:10
Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)
07/06/25 - 12:25
Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)
06/05/25 - 17:41
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)
18/04/25 - 18:11
Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)
18/03/25 - 11:54
Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)
14/03/25 - 16:29
The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)
17/12/24 - 12:56
2025 Annual Calendar of Corporate Events (104.79 KB)
11/11/24 - 7:38
Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)
05/11/24 - 16:27
Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
27/09/24 - 7:35
Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)
09/09/24 - 13:11
Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
05/09/24 - 11:17
DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)
04/09/24 - 11:36
Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)
29/07/24 - 15:55
DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
16/07/24 - 8:31
Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
05/06/24 - 5:07
Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
16/05/24 - 19:56
Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
10/05/24 - 15:21
Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
24/04/24 - 15:38
Shareholders' Meeting 2024 (159.72 KB)
16/04/24 - 8:20
Communication on total amount of voting rights (135.47 KB)
15/03/24 - 13:35
The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
13/03/24 - 10:23
Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
03/03/24 - 19:32
Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
25/01/24 - 7:48
Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
06/11/23 - 15:44
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
24/10/23 - 15:03
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
27/07/23 - 14:27
Update 2023 Annual Calendar of Corporate Events (104.1 KB)
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
17/07/23 - 7:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
03/07/23 - 11:48
Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
13/06/23 - 15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
07/06/23 - 14:40
Communication of total amount of voting rights (7 June 2023) (141.14 KB)
05/06/23 - 21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
26/05/23 - 7:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
28/04/23 - 12:52
Shareholders' Meeting 2023 (373.48 KB)
27/03/23 - 15:52
Update 2023 Annual Calendar of Corporate Events (483.89 KB)
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
17/03/23 - 22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
28/02/23 - 16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
13/02/23 - 22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
07/02/23 - 12:01
Update 2023 Annual Calendar of Corporate Events (288.3 KB)
01/12/22 - 18:30
2023 Annual Calendar of Corporate Events (288 KB)
09/11/22 - 7:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
07/11/22 - 7:12
DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
05/10/22 - 6:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
14/09/22 - 0:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
14/07/22 - 20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
07/06/22 - 18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
20/05/22 - 7:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
09/05/22 - 7:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
06/05/22 - 17:33
Update 2022 Annual Calendar of Corporate Events (285.68 KB)
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
02/05/22 - 12:55
Publication of the summary report of the votes cast (280.95 KB)
29/04/22 - 16:26
Shareholders' meeting 2022 (166.12 KB)
22/04/22 - 12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
13/04/22 - 16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
08/04/22 - 19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
08/04/22 - 9:53
Update annual calendar of corporate events 2022 (288.09 KB)
05/04/22 - 9:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
04/04/22 - 18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
16/03/22 - 17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
08/03/22 - 7:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
13/01/22 - 7:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
21/12/21 - 11:07
2022 Annual Calendar of Corporate Events (296.13 KB)
16/12/21 - 22:47
DiaSorin 2022-2025 Strategic Plan (552.15 KB)
30/11/21 - 19:10
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
29/11/21 - 7:06
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
23/11/21 - 7:10
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
11/11/21 - 16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
05/11/21 - 11:22
Weekly report treasury shares buy-back (2.15 MB)
02/11/21 - 20:00
Conclusion treasury shares buy-back plan (294.67 KB)
02/11/21 - 19:57
Weekly report treasury shares buy-back (3.5 MB)
27/10/21 - 16:35
Issuance of the "Physical Settlement Notice" (517.5 KB)
07/10/21 - 11:45
Publication of the summary report of the votes (290.08 KB)
04/10/21 - 12:27
The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
18/09/21 - 8:16
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
30/07/21 - 18:43
Start up of the treasury shares buy-back plan (773.96 KB)
30/07/21 - 12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
22/07/21 - 18:28
Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
14/07/21 - 15:05
DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
09/07/21 - 7:34
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
21/06/21 - 18:49
The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
15/06/21 - 6:56
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
07/06/21 - 15:16
Communication on total amount of voting rights (563.42 KB)
03/06/21 - 7:47
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
25/05/21 - 7:03
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
21/05/21 - 7:02
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
20/05/21 - 8:27
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
14/05/21 - 16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
28/04/21 - 17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
28/04/21 - 7:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
22/04/21 - 15:58
Shareholders' meeting April 22, 2021 (422.91 KB)
21/04/21 - 7:02
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
20/04/21 - 18:58
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
14/04/21 - 10:05
Communication voting rights amount (544.6 KB)
12/04/21 - 11:08
Weekly report treasury shares buy-back (914.42 KB)
11/04/21 - 19:47
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
06/04/21 - 8:53
Start up buy-back plan (774.02 KB)
06/04/21 - 7:06
DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
30/03/21 - 7:01
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
29/03/21 - 7:02
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
11/03/21 - 16:37
Dividend coupon date correction (414.99 KB)
11/03/21 - 15:31
Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
23/02/21 - 6:11
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
27/01/21 - 18:50
2021 Annual Calendar of Corporate Events (209.87 KB)
11/01/21 - 18:43
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
29/12/20 - 18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
17/12/20 - 17:57
DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
07/12/20 - 10:35
Communication on total amount of voting rights (563.18 KB)
04/12/20 - 16:14
Form 3F (November 2020) (10.2 KB)
01/12/20 - 6:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
11/11/20 - 12:41
North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
26/10/20 - 18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
23/10/20 - 19:41
Conclusion treasury shares buy-back plan (314.28 KB)
23/10/20 - 19:37
Weekly report treasury shares buy-back (436.92 KB)
16/10/20 - 18:28
Weekly report treasury shares buy-back (425.19 KB)
01/10/20 - 7:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
01/10/20 - 7:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
23/09/20 - 7:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
16/09/20 - 14:30
Update Annual Calendar of Corporate Events 2020 (222.26 KB)
16/09/20 - 7:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
08/09/20 - 7:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
07/09/20 - 18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
06/08/20 - 7:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
31/07/20 - 16:04
Weekly report treasury shares buy-back (380.16 KB)
30/07/20 - 13:16
North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
24/07/20 - 17:19
Weekly report treasury shares buy-back (363.73 KB)
17/07/20 - 18:19
Weekly report treasury shares buy-back (360.09 KB)
10/07/20 - 18:23
Weekly report treasury shares buy-back (374 KB)
09/07/20 - 7:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
07/07/20 - 7:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
30/06/20 - 7:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
19/06/20 - 17:20
Weekly report treasury shares buy-back (399.38 KB)
17/06/20 - 16:09
Start up of the treasury shares buy-back plan (481.28 KB)
12/06/20 - 7:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
10/06/20 - 15:40
Shareholders' Meeting June 10, 2020 (308.25 KB)
03/06/20 - 14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
02/06/20 - 14:58
Communication total amount voting rights (record date) (267.83 KB)
18/05/20 - 11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
13/05/20 - 13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
25/04/20 - 16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
17/04/20 - 18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
07/04/20 - 7:14
IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
26/03/20 - 18:14
Update Annual Calendar of Corporate Events 2020 (277.25 KB)
21/03/20 - 20:29
Shareholders' Meeting date change (288.23 KB)
20/03/20 - 7:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
13/03/20 - 17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
11/03/20 - 13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
10/03/20 - 8:20
DiaSorin - Development of Coronavirus test (404.03 KB)
02/03/20 - 8:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
07/02/20 - 8:06
Communication on total amount of voting rights (281.13 KB)
15/01/20 - 16:51
Annual Calendar of Corporate Events 2020 (124.73 KB)
16/12/19 - 14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
06/12/19 - 18:12
Press Release (262.61 KB)
06/12/19 - 18:11
Press Release (262.7 KB)
06/12/19 - 18:08
Communication on total amount of voting rights (281.87 KB)
27/11/19 - 7:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
11/11/19 - 9:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
06/11/19 - 13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
30/10/19 - 9:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
22/10/19 - 14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
07/10/19 - 10:20
Communication on total amount of voting rights (282.21 KB)
24/09/19 - 10:10
DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
31/07/19 - 13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
10/06/19 - 18:23
DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
05/06/19 - 7:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
29/05/19 - 15:06
DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
09/05/19 - 13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
06/05/19 - 15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
30/04/19 - 12:28
Update Annual Calendar of Corporate Events 2019 (249.43 KB)
24/04/19 - 17:24
DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
12/04/19 - 8:59
Communication on total amount of voting rights (320.44 KB)
05/04/19 - 9:33
Communication on total amount of voting rights (342.47 KB)
03/04/19 - 20:18
Lists publication (79.68 KB)
03/04/19 - 10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
14/03/19 - 14:16
Growth in revenues, profitability and net profit in 2018 (1.03 MB)
07/03/19 - 11:45
Communication on total amount of voting rights (350.08 KB)
06/03/19 - 8:45
A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
07/02/19 - 15:15
Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
31/01/19 - 22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
03/01/19 - 13:30
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
21/12/18 - 11:30
DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
04/12/18 - 8:00
DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
19/11/18 - 15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
07/11/18 - 13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
17/10/18 - 11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
12/10/18 - 11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
09/10/18 - 11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
17/09/18 - 11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
07/08/18 - 8:45
Communication on total amount of voting rights (305.24 KB)
02/08/18 - 12:45
The Board of Directors approves the results for the first half of 2018 (883.1 KB)
27/07/18 - 12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
03/07/18 - 18:30
Conclusion treasury shares buy-back plan (397.33 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back July 2018) (6.59 KB)
03/07/18 - 18:30
Report treasury shares buy-back (287.99 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back June 2018) (8.69 KB)
29/06/18 - 18:15
Weekly report treasury shares buy-back (290.62 KB)
22/06/18 - 20:30
Weekly report treasury shares buy-back (290.6 KB)
15/06/18 - 21:00
Weekly report treasury shares buy-back (290.62 KB)
12/06/18 - 14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
08/06/18 - 23:15
Weekly report treasury shares buy-back (290.24 KB)
04/06/18 - 13:15
Annex 3F (treasury shares buy back May 2018) (8.54 KB)
01/06/18 - 20:15
Weekly report treasury shares buy-back (290.38 KB)
25/05/18 - 22:30
Weekly report treasury shares buy-back (289.97 KB)
19/05/18 - 1:45
Weekly report treasury shares buy-back (289.76 KB)
11/05/18 - 20:15
Weekly report treasury shares buy-back (290.77 KB)
08/05/18 - 14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
03/05/18 - 20:15
Start up treasury shares buy-back plan (354.27 KB)
24/04/18 - 14:00
Annex 3F (treasury shares buy back) (7.77 KB)
23/04/18 - 18:30
Annual General Meeting 2018 (589.65 KB)
19/04/18 - 21:15
Conclusion treasury shares buy-back plan (397.59 KB)
19/04/18 - 21:00
Weekly report treasury shares buy-back (289.29 KB)
13/04/18 - 20:30
Weekly report treasury shares buy-back (290.07 KB)
06/04/18 - 19:45
Weekly report treasury shares buy-back (288.33 KB)
05/04/18 - 12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
04/04/18 - 20:00
Start up treasury shares buy-back plan (346.04 KB)
28/03/18 - 18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
07/03/18 - 15:30
DiaSorin: FY 2017 Results (1.14 MB)
30/01/18 - 11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
12/12/17 - 13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
29/11/17 - 19:30
Resignation of a Strategic Executive of the Company (233.58 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
29/09/17 - 14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
21/09/17 - 12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
28/07/17 - 14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
25/07/17 - 21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
10/07/17 - 13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
23/06/17 - 9:30
DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
22/06/17 - 19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
23/05/17 - 11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
16/05/17 - 13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
21/04/17 - 18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
06/04/17 - 18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
08/03/17 - 15:30
The Board of Directors approves the results for FY'16 (1.13 MB)
21/02/17 - 11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
26/01/17 - 12:45
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
19/12/16 - 10:00
Co-optation of a Director (333.18 KB)
10/11/16 - 1:00
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
02/11/16 - 1:00
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
30/08/16 - 2:00
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
22/08/16 - 2:00
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
04/08/16 - 2:00
The Board of Directors approves results for H1'16 (697.16 KB)
28/07/16 - 2:00
DiaSorin starts selling Vitamin D in Japan (724.4 KB)
14/07/16 - 2:00
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
10/06/16 - 2:00
Weekly report treasury shares buy-back (289.83 KB)
10/06/16 - 2:00
Conclusion buy-back plan (367.77 KB)
07/06/16 - 2:00
DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
03/06/16 - 2:00
Weekly report treasury shares buy-back (290.21 KB)
30/05/16 - 2:00
Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
27/05/16 - 2:00
Weekly report treasury shares buy-back (289.34 KB)
20/05/16 - 2:00
Weekly report treasury shares buy-back (290.09 KB)
13/05/16 - 2:00
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
12/05/16 - 2:00
Start up treasury shares buy-back plan (305.9 KB)
09/05/16 - 2:00
The Board of Directors approves the results for Q1'16 (632.78 KB)
28/04/16 - 2:00
Shareholders' Meeting FY 2015 (365.15 KB)
30/03/16 - 2:00
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
09/03/16 - 1:00
The Board of Directors approves the results for FY'15 (785.08 KB)
11/11/15 - 1:00
The Board of Directors approves the results for Q3'15 (778.06 KB)
09/09/15 - 2:00
DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
30/07/15 - 2:00
H1'15 Results (777.06 KB)
20/07/15 - 2:00
DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
28/05/15 - 2:00
DiaSorin launches the test for Campylobacter (241.86 KB)
12/05/15 - 2:00
DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
12/05/15 - 2:00
The Board of Directors approves the results for Q1'15 (553.96 KB)
29/04/15 - 2:00
DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
23/04/15 - 2:00
DiaSorin supports the Pinocchio Project (251.16 KB)
22/04/15 - 2:00
The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
22/04/15 - 2:00
Shareholders' meeting approves FY Results 2014 (105.93 KB)
14/04/15 - 2:00
DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
10/04/15 - 2:00
Investor Day-save the date (107.93 KB)
24/03/15 - 1:00
DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)
03/03/15 - 1:00
The Board of Directors approves the results for FY'14 (783.03 KB)
24/02/15 - 1:00
DiaSorin supports Emergency in Sudan (612.64 KB)
13/02/15 - 1:00
DiaSorin teams with FISIP for Progetto talenti (612.64 KB)
14/01/15 - 1:00
DiaSorin launches the test for Calprotectin (259.67 KB)
16/12/14 - 1:00
FDA approves 1,25 Vitamin D in the US market (239.73 KB)
09/12/14 - 1:00
DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
14/11/14 - 1:00
The Board of Directors approves the results for Q3'14 (785.42 KB)
07/10/14 - 2:00
DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
18/09/14 - 2:00
DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
01/08/14 - 2:00
The Board of Directors approves the results for H1'14 (812.25 KB)
22/07/14 - 2:00
DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
30/06/14 - 2:00
DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
03/06/14 - 2:00
DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
09/05/14 - 2:00
The Board of Directors approves the results for Q1'14 (573.05 KB)
23/04/14 - 2:00
Shareholders' meeting approves FY Results 2013 (107.65 KB)
06/03/14 - 1:00
The Board of Directors approves the results for FY'13 (753.73 KB)
18/02/14 - 1:00
DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
11/02/14 - 1:00
DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
28/01/14 - 1:00
DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)
24/01/14 - 1:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
09/01/14 - 1:00
DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
08/11/13 - 1:00
The Board of Directors approves the Q3'13 Results (766.57 KB)
29/10/13 - 1:00
DiaSorin signes a 5-year agreement with Roche (432.42 KB)
25/10/13 - 2:00
DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
10/10/13 - 2:00
DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
24/09/13 - 2:00
DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
01/08/13 - 2:00
The Board of Directors approves the results for the H1 '13 (386.67 KB)
24/07/13 - 2:00
DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
11/07/13 - 2:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
28/06/13 - 2:00
DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
20/06/13 - 2:00
DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
10/05/13 - 2:00
The Board of Directors approves the results for Q1'13 (763.61 KB)
02/05/13 - 2:00
Compensation Commitee-Errata corrige (179.38 KB)
22/04/13 - 2:00
Shareholders' meeting approves FY Results 2012 (57.22 KB)
17/04/13 - 2:00
FDA approves the Aldosterone assay (439.58 KB)
02/04/13 - 2:00
DiaSorin signs an agreement with Seegene (243.64 KB)
08/03/13 - 1:00
The BoD approves FY 2012 results (477.24 KB)
07/03/13 - 1:00
Notification of changes in share capital (46.86 KB)
07/03/13 - 1:00
Notice availability By-Laws (36.87 KB)
07/02/13 - 1:00
Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
07/02/13 - 1:00
Notification of changes in share capital (46.89 KB)
07/02/13 - 1:00
Notice availability By-Laws (139.13 KB)
30/01/13 - 1:00
The Board of Directors approves the results for the FY '12 (477.24 KB)
29/01/13 - 1:00
Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
20/12/12 - 1:00
Shareholders' meeting (55.42 KB)
07/11/12 - 1:00
The BoD approves Q3'12 results (280.42 KB)
03/08/12 - 2:00
The BoD approves H1'12 results (279.41 KB)
30/07/12 - 2:00
DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)
27/06/12 - 2:00
Notification of changes in share capital (335.97 KB)
11/05/12 - 2:00
The BoD approves Q1'12 results (122.04 KB)
04/05/12 - 2:00
NorDiag acquisition (88.87 KB)
23/04/12 - 2:00
2011 statutory financial statement approval (182.29 KB)
10/04/12 - 2:00
Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
02/04/12 - 2:00
Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
30/03/12 - 2:00
Financial calendar update (176.51 KB)
22/03/12 - 1:00
Stock options to employees (175.38 KB)
12/03/12 - 1:00
Agreement with Sonic Healthcare on Vitamin D (179.85 KB)
09/03/12 - 1:00
The BoD approves FY 2011 results (357.11 KB)
07/03/12 - 1:00
Notification of changes in share capital (46.84 KB)
17/02/12 - 1:00
DiaSorin became a member of the ISBT (178.96 KB)
09/02/12 - 1:00
Notice of change in share capital (46.97 KB)
02/02/12 - 1:00
FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
27/01/12 - 1:00
2012 Financial calendar update (177.74 KB)
25/01/12 - 1:00
Dividend distribution in June (115.61 KB)
19/01/12 - 1:00
Prize for best Italian Company in R&D in the UK (183.95 KB)
13/01/12 - 1:00
2012 Financial calendar (176.51 KB)
12/01/12 - 1:00
New anti HBs II (available outside the US and Canada only) (196.83 KB)
23/12/11 - 1:00
Financial instruments to employees (57.22 KB)
19/12/11 - 1:00
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
19/11/11 - 1:00
Buy-back plan (35.47 KB)
18/11/11 - 1:00
Financial instruments to employees (56.82 KB)
11/11/11 - 1:00
The BoD approves Q3'11 results (334.35 KB)
28/10/11 - 2:00
Buy-back plan (103.99 KB)
25/10/11 - 2:00
Buy-back plan (104.72 KB)
18/10/11 - 2:00
Buy-back plan (136.18 KB)
17/10/11 - 2:00
2011-2015 Business Plan: a new business wave (195.1 KB)
10/10/11 - 2:00
New Chief Financial Officer (196.26 KB)
06/10/11 - 2:00
Cardinal Health: agreement extended to 2014 (192.57 KB)
04/10/11 - 2:00
Buy-back plan (204.92 KB)
01/09/11 - 2:00
Resignation of Chief Financial Officer (177.77 KB)
31/08/11 - 2:00
2011 Financial calendar update (176.4 KB)
03/08/11 - 2:00
The BoD approves H1'11 results (324.48 KB)
11/07/11 - 2:00
Voluntarily removal from the STAR segment (194.93 KB)
13/05/11 - 2:00
The BoD approves Q1'11 results (307.28 KB)
11/05/11 - 2:00
DiaSorin and Labcorp extend strategic business relationship (100.01 KB)
06/05/11 - 2:00
Agreement with Precision System Science Co., LTD (171.54 KB)
28/04/11 - 2:00
The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
16/03/11 - 1:00
The BoD approves FY'10 results (368.28 KB)
16/03/11 - 1:00
Dividend information amendment (159.83 KB)
28/02/11 - 1:00
2011 Financial calendar update (179.92 KB)
19/02/11 - 1:00
Notice of change in share capital (5.28 KB)
18/02/11 - 1:00
Buy-back plan (134.06 KB)
17/02/11 - 1:00
Financial instruments to employees (56.37 KB)
16/02/11 - 1:00
Buy-back plan (105.2 KB)
15/02/11 - 1:00
Buy-back plan (91.38 KB)
14/02/11 - 1:00
The BoD approves Q4'10 results (161 KB)
31/01/11 - 1:00
Buy-back plan (105.05 KB)
29/01/11 - 1:00
Buy-back plan (105.2 KB)
28/01/11 - 1:00
Buy-back plan (105.04 KB)
27/01/11 - 1:00
Buy-back plan (105.04 KB)
26/01/11 - 1:00
FDA approves the LIAISON XL (194.2 KB)
25/01/11 - 1:00
Buy-back plan (105.22 KB)
24/01/11 - 1:00
Buy-back plan (104.72 KB)
21/01/11 - 1:00
Buy-back plan (105.05 KB)
20/01/11 - 1:00
Buy-back plan (91.39 KB)
19/01/11 - 1:00
Buy-back plan (105.31 KB)
18/01/11 - 1:00
Buy-back plan (35.47 KB)
17/01/11 - 1:00
Buy-back plan (134.01 KB)
17/01/11 - 1:00
The Sonic Healthcare Group chooses DiaSorin (181.71 KB)
16/01/11 - 1:00
2011 Financial calendar (179.49 KB)
22/12/10 - 1:00
2011 Financial calendar (180.28 KB)
20/12/10 - 1:00
Dividend may be distributed in June (445.78 KB)
02/12/10 - 1:00
Comment on position Paper on Vitamin D (53.46 KB)
24/11/10 - 1:00
Change in share capital (46.85 KB)
18/11/10 - 1:00
Financial instruments to employees (48.33 KB)
05/11/10 - 1:00
The BoD approves Q3'10 results (414.16 KB)
02/11/10 - 1:00
Change in share capital (313.61 KB)
08/10/10 - 2:00
2010 Financial calendar update (174.1 KB)
30/09/10 - 2:00
Change in share capital (5.25 KB)
24/09/10 - 2:00
Financial instruments to employees (48.81 KB)
16/09/10 - 2:00
Stock options exercised by key managers (195.67 KB)
02/09/10 - 2:00
Financial instruments to employees (24.27 KB)
06/08/10 - 2:00
The BoD approves H1'10 results (287.11 KB)
07/07/10 - 2:00
Agreement with Meridian Inc. (182.7 KB)
06/07/10 - 2:00
2010 Financial calendar update (174.1 KB)
02/07/10 - 2:00
Financial instruments to employees (24.37 KB)
01/06/10 - 2:00
Acquisition of MUREX product line (102.6 KB)
14/05/10 - 2:00
The BoD approves Q1'10 results (254.05 KB)
27/04/10 - 2:00
Approval of statutory financial statements (182.99 KB)
20/04/10 - 2:00
2010 Financial calendar update (168.23 KB)
14/04/10 - 2:00
Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
09/04/10 - 2:00
China approves new prenatal screening product line on LIAISON (141.08 KB)
02/04/10 - 2:00
Financial instruments to employees (27.79 KB)
22/03/10 - 1:00
The BoD approves FY 2009 results (306.02 KB)
10/03/10 - 1:00
Acquisition of MUREX product line (45.5 KB)
01/03/10 - 1:00
2010 Financial calendar update (192.49 KB)
12/02/10 - 1:00
The BoD approves Q4'09 results (213.8 KB)
18/01/10 - 1:00
2010 Financial calendar (103 KB)
24/12/09 - 1:00
Financial instruments to employees (26.76 KB)
30/10/09 - 1:00
The BoD approves Q3'09 results (212.92 KB)
12/10/09 - 2:00
Strengthening of group's R&D team (99.72 KB)
08/10/09 - 2:00
2009 Financial calendar update (97.3 KB)
05/10/09 - 2:00
Financial instruments to employees (27.08 KB)
06/08/09 - 2:00
The BoD approves H1'09 results (214.79 KB)
08/06/09 - 2:00
2009 Financial calendar update (97.33 KB)
18/05/09 - 2:00
Financial instruments to employees (26.65 KB)
10/04/09 - 2:00
Corporate Governance Report at December 2008. (97.57 KB)
08/04/09 - 2:00
2009 Financial calendar update (103.88 KB)
19/03/09 - 1:00
The BoD approves FY 2008 results (221.59 KB)
20/02/09 - 1:00
Financial instruments to employees (26.39 KB)
13/02/09 - 1:00
The BoD approves Q4'08 results (170.79 KB)
28/01/09 - 1:00
2009 Financial calendar (93.96 KB)
08/01/09 - 1:00
FDA clearance to five LIAISON products (96.84 KB)
23/12/08 - 1:00
Financial instruments to employees (26.19 KB)
21/11/08 - 1:00
Financial instruments to employees (23.66 KB)
13/11/08 - 1:00
The BoD approves Q3'08 results (171.93 KB)
22/09/08 - 2:00
Agreement in Japan with Advanced Life Science Institute (99.16 KB)
08/08/08 - 2:00
The BoD approves H1'08 results (194.3 KB)
09/07/08 - 2:00
Acquisition of Biotrin (99.08 KB)
16/05/08 - 2:00
Financial instruments to employees (23.28 KB)
15/05/08 - 2:00
Results for Q1'08 (159.78 KB)
24/04/08 - 2:00
2007 statutory financial Statements approved (93.67 KB)
21/04/08 - 2:00
2008 Financial calendar update (93.56 KB)
19/03/08 - 1:00
The BoD approves FY 2007 results (198.25 KB)
14/02/08 - 1:00
The BoD approves Q4'07 results (170.91 KB)
29/01/08 - 1:00
2008 Financial calendar (88.78 KB)
07/01/08 - 1:00